Literature DB >> 31055787

Atopic Keratoconjunctivitis: Pharmacotherapy for the Elderly.

Erminia Ridolo1, P Kihlgren2, I Pellicelli2, M C Nizi2, F Pucciarini2, C Incorvaia3.   

Abstract

Among the different forms of allergic conjunctivitis, atopic keratoconjunctivitis has distinct characteristics, defined by a more common onset in late adolescence or early adulthood, but also affecting the elderly, and with a higher prevalence in male individuals. However, the prevalence of atopic keratoconjunctivitis is scarcely investigated, and the data are often uncertain because other allergic nasal or respiratory disorders occur concomitantly. Mast cells, eosinophils, basophils, and T cells are involved in the pathogenesis of atopic keratoconjunctivitis. Despite its denomination as atopic, negative responses to skin tests or in-vitro immunoglobulin E tests are common. In fact, atopic keratoconjunctivitis can be attributed to a combination of T-helper-1 and T-helper-2 responses, but a higher prominence for T-helper-1 cells was found. The most common symptoms of atopic keratoconjunctivitis are bilateral ocular itching, burning, and tearing with a perennial presentation, although some patients may have seasonal exacerbations in winter or summer. Other symptoms such as photophobia, blurred vision, and mucous chewy discharge, owing to the accumulation of cells and mucin, may occur. The diagnosis of atopic keratoconjunctivitis is mainly clinical, as accepted diagnostic criteria or laboratory tests are not available. The treatment of atopic keratoconjunctivitis is aimed at controlling symptoms, decreasing relapse and exacerbations, and reducing vision loss. Therapeutic options comprise topical ophthalmic drops, including cromones, antihistamines, corticosteroids, and calcineurin inhibitors. Topical ointments are also available for corticosteroids and calcineurin inhibitors. Severe forms may require systemic medications including antihistamines, corticosteroids, and calcineurin inhibitors. Atopic keratoconjunctivitis therapy in the elderly does not differ from the adult population, but the occurrence of multi-morbidities and concomitant drug treatment, which are common in this age group, requires a careful evaluation to determine appropriate and personalized treatment.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31055787     DOI: 10.1007/s40266-019-00676-7

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  68 in total

Review 1.  Establishing the place in therapy of bilastine in the treatment of allergic rhinitis according to ARIA: evidence review.

Authors:  Jean Bousquet; Ignacio Ansótegui; G Walter Canonica; Torsten Zuberbier; Carlos E Baena-Cagnani; Claus Bachert; Alvaro A Cruz; Sandra N González; Piotr Kuna; Mario Morais-Almeida; Joaquim Mullol; Dermot P Ryan; Mario Sánchez-Borges; Román Valiente; Martin K Church
Journal:  Curr Med Res Opin       Date:  2011-12-22       Impact factor: 2.580

Review 2.  Atopic dermatitis and keratoconjunctivitis.

Authors:  Brett Bielory; Leonard Bielory
Journal:  Immunol Allergy Clin North Am       Date:  2010-08       Impact factor: 3.479

3.  Atopic dermatitis and its ophthalmic complications.

Authors:  L Oshinskie; C Haine
Journal:  J Am Optom Assoc       Date:  1982-11

4.  Chemokine receptor gene expression in giant papillae of atopic keratoconjunctivitis.

Authors:  Satoru Yamagami; Nobuyuki Ebihara; Seiichi Yokoo Shiro Amano
Journal:  Mol Vis       Date:  2005-03-10       Impact factor: 2.367

Review 5.  Allergic and immunologic disorders of the eye. Part II: ocular allergy.

Authors:  L Bielory
Journal:  J Allergy Clin Immunol       Date:  2000-12       Impact factor: 10.793

6.  Conjunctival provocation with airborne allergen in patients with atopic keratoconjunctivitis.

Authors:  E Nivenius; I Van der Ploeg; Guro Gafvelin; M Van Hage; P G Montan
Journal:  Clin Exp Allergy       Date:  2011-09-20       Impact factor: 5.018

Review 7.  Practical approach to diagnosis and treatment of ocular allergy: a 1-year systematic review.

Authors:  Sergio Bonini; Claudia Gramiccioni; Matteo Bonini; Megon Bresciani
Journal:  Curr Opin Allergy Clin Immunol       Date:  2007-10

8.  Presentation of the steroid psychoses.

Authors:  R C Hall; M K Popkin; S K Stickney; E R Gardner
Journal:  J Nerv Ment Dis       Date:  1979-04       Impact factor: 2.254

9.  Mycophenolate mofetil for ocular inflammation.

Authors:  Ebenezer Daniel; Jennifer E Thorne; Craig W Newcomb; Siddharth S Pujari; R Oktay Kaçmaz; Grace A Levy-Clarke; Robert B Nussenblatt; James T Rosenbaum; Eric B Suhler; C Stephen Foster; Douglas A Jabs; John H Kempen
Journal:  Am J Ophthalmol       Date:  2009-12-30       Impact factor: 5.258

Review 10.  Immunosuppressive therapy for eye diseases: Effectiveness, safety, side effects and their prevention.

Authors:  Dana M Hornbeak; Jennifer E Thorne
Journal:  Taiwan J Ophthalmol       Date:  2015-05-12
View more
  1 in total

Review 1.  Systemic diseases and the cornea.

Authors:  Ruchi Shah; Cynthia Amador; Kati Tormanen; Sean Ghiam; Mehrnoosh Saghizadeh; Vaithi Arumugaswami; Ashok Kumar; Andrei A Kramerov; Alexander V Ljubimov
Journal:  Exp Eye Res       Date:  2021-01-21       Impact factor: 3.467

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.